Detailansicht

Wissensnetz

Person

Helmut R. Salih (1970-)

Name	Helmut R. Salih
Zeit	1970- (Lebensdaten)
Ort	Deutschland
Variante	Helmut Rainer Salih
Weitere Angaben	Habil. Fach Innere Medizin
Datensatztyp	Person
GND-Nummer	120086565
Datensatz-ID	120086565
Beteiligt an alle anzeigen Induction of NK cell reactivity against acute myeloid leukemia by Fc-optimized CD276 (B7-H3) antibody TOFIMS mass spectrometry-based immunopeptidomics refines tumor antigen identification Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiency Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease In vivo kinetics of early, non-random methylome and transcriptome changes induced by DNA-hypomethylating treatment in primary AML blasts In vivo kinetics of early, non-random methylome and transcriptome changes induced by DNA-hypomethylating treatment in primary AML blasts The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma Expression of the immune checkpoint modulator OX40 indicates poor survival in acute myeloid leukemia BCR::ABL1 tyrosine kinase inhibitors hamper the therapeutic efficacy of blinatumomab in vitro Identification of CD105 (endoglin) as novel risk marker in CLL Platelet-expressed immune checkpoint regulator GITRL in breast cancer SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition CD105 (endoglin) as risk marker in AML patients undergoing stem cell transplantation Identification of CD318 (CDCP1) as novel prognostic marker in AML An IgG‐based bispecific antibody for improved dual targeting in PSMA‐positive cancer Bispecific NKG2D-CD3 and NKG2D-CD16 fusion proteins for induction of NK and T cell reactivity against acute myeloid leukemia The challenges of translation Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia—results of the AMLSG 11-08 trial The novel deubiquitinase inhibitor b-AP15 induces direct and NK cell-mediated antitumor effects in human mantle cell lymphoma The BCR-ABL inhibitor nilotinib influences phenotype and function of monocyte-derived human dendritic cells All-trans retinoic acid as adjunct to intensive treatment in younger adult patients with acute myeloid leukemia: results of the randomized AMLSG 07-04 study Erratum to: The transcription factor MITF is a critical regulator of GPNMB expression in dendritic cells Dronabinol has preferential antileukemic activity in acute lymphoblastic and myeloid leukemia with lymphoid differentiation patterns The transcription factor MITF is a critical regulator of GPNMB expression in dendritic cells Expression und Freisetzung immunregulatorischer Oberflächenmoleküle in der Interaktion von Tumor und Immunsystem Einfluß von Heparin auf humane Granulocyten und Monocyten : Anwendung durchflußzytometrischer Verfahren

Hinweis

Die Betaversion beinhaltet noch nicht alle Funktionen und Informationen des Katalogs des DNB-Portals. Falls Sie Informationen vermissen oder ein Medium bestellen wollen, besuchen Sie bitte die entsprechende Seite im Katalog des DNB-Portals über folgenden Link:

Katalog der Deutschen Nationalbibliothek

Helmut R. Salih (1970-)

Induction of NK cell reactivity against acute myeloid leukemia by Fc-optimized CD276 (B7-H3) antibody

TOFIMS mass spectrometry-based immunopeptidomics refines tumor antigen identification

Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiency

Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease

In vivo kinetics of early, non-random methylome and transcriptome changes induced by DNA-hypomethylating treatment in primary AML blasts

In vivo kinetics of early, non-random methylome and transcriptome changes induced by DNA-hypomethylating treatment in primary AML blasts

The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma

Expression of the immune checkpoint modulator OX40 indicates poor survival in acute myeloid leukemia

BCR::ABL1 tyrosine kinase inhibitors hamper the therapeutic efficacy of blinatumomab in vitro

Identification of CD105 (endoglin) as novel risk marker in CLL

Platelet-expressed immune checkpoint regulator GITRL in breast cancer

SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition

CD105 (endoglin) as risk marker in AML patients undergoing stem cell transplantation

Identification of CD318 (CDCP1) as novel prognostic marker in AML

An IgG‐based bispecific antibody for improved dual targeting in PSMA‐positive cancer

Bispecific NKG2D-CD3 and NKG2D-CD16 fusion proteins for induction of NK and T cell reactivity against acute myeloid leukemia

The challenges of translation

Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia—results of the AMLSG 11-08 trial

The novel deubiquitinase inhibitor b-AP15 induces direct and NK cell-mediated antitumor effects in human mantle cell lymphoma

The BCR-ABL inhibitor nilotinib influences phenotype and function of monocyte-derived human dendritic cells

All-trans retinoic acid as adjunct to intensive treatment in younger adult patients with acute myeloid leukemia: results of the randomized AMLSG 07-04 study

Erratum to: The transcription factor MITF is a critical regulator of GPNMB expression in dendritic cells

Dronabinol has preferential antileukemic activity in acute lymphoblastic and myeloid leukemia with lymphoid differentiation patterns

The transcription factor MITF is a critical regulator of GPNMB expression in dendritic cells

Expression und Freisetzung immunregulatorischer Oberflächenmoleküle in der Interaktion von Tumor und Immunsystem

Einfluß von Heparin auf humane Granulocyten und Monocyten : Anwendung durchflußzytometrischer Verfahren